Skip to main content
. 2020 Dec 1;9(12):3903. doi: 10.3390/jcm9123903

Figure 5.

Figure 5

Distribution of the CsA AUC(0–12) exposure values in the study groups: CsA + MMF and CsA monotherapy; MMF—mycophenolate mofetil; CsA—cyclosporine. Scatter plots display the individual AUC(0–12) exposure values’ distribution from the median in CsA-receiving study groups (median ± SE): 3.02 ± 0.13 mg/h/L (CsA + MMF, post-transplantation time: 1–5 years) versus 3.56 ± 0.55 mg/h/L (CsA monotherapy, post-transplantation time: 1–5 years); 2.84 ± 0.80 mg/h/L (CsA + MMF, post-transplantation time > 5 years) versus 2.91 ± 0.10 mg/h/L (CsA monotherapy, post-transplantation time > 5 years). Respectively, the mean values (mean ± SD) were as follows: 3.31 ± 0.94 µg/h/L (Tacro + MMF, post-transplantation time: 1–5 years) versus 3.01 ± 0.96 µg/h/L (Tacro monotherapy, post-transplantation time: 1–5 years); 2.96 ± 0.79 µg/h/L (Tacro + MMF, post-transplantation time > 5 years) versus 2.98 ± 0.70 µg/h/L (Tacro monotherapy, post-transplantation time > 5 years).